{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:30:55Z","timestamp":1789140655679,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18376-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:50:01Z","timestamp":1759171801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Elvine Zhong Oen","family":"Neo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Wei Onn","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Hong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Bee Yong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Mun Yoong","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Fang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Wei Yi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Qiang","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Yu Hang","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng Xian","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Jhi Wen","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustinus","family":"Laude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin Siang Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tock Han","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Yi\u2019an","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Kiong","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"2","key":"18376_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2 (2), e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1 (2014).","journal-title":"Lancet Glob Health"},{"issue":"6","key":"18376_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","volume":"244","author":"R Flores","year":"2021","unstructured":"Flores, R. et al. Age-Related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica 244 (6), 495\u2013511. https:\/\/doi.org\/10.1159\/000517520 (2021).","journal-title":"Ophthalmologica"},{"key":"18376_CR3","doi-asserted-by":"publisher","unstructured":"Flaxel, C. J. et al. Age-Related macular degeneration preferred practice Pattern(R). Ophthalmology 127 (1). https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.024 (2020). p. P1-P65.","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"18376_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S231913","volume":"16","author":"CS Tan","year":"2022","unstructured":"Tan, C. S. et al. Neovascular Age-Related macular degeneration (nAMD): A review of emerging treatment options. Clin. Ophthalmol. 16, 917\u2013933. https:\/\/doi.org\/10.2147\/OPTH.S231913 (2022).","journal-title":"Clin. Ophthalmol."},{"key":"18376_CR5","doi-asserted-by":"publisher","unstructured":"Khan, M. et al. Targeting angiopoietin in retinal vascular diseases: A literature review and summary of clinical trials involving faricimab. Cells 9 (8). https:\/\/doi.org\/10.3390\/cells9081869 (2020).","DOI":"10.3390\/cells9081869"},{"issue":"9","key":"18376_CR6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani, A. M. et al. Efficacy of every four monthly and quarterly dosing of faricimab vs Ranibizumab in neovascular Age-Related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 138 (9), 964\u2013972. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699 (2020).","journal-title":"JAMA Ophthalmol."},{"issue":"10326","key":"18376_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier, J. S. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399 (10326), 729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1 (2022).","journal-title":"Lancet"},{"key":"18376_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung, E. H. et al. Initial Real-World experience with faricimab in Treatment-Resistant neovascular Age-Related macular degeneration. Clin. Ophthalmol. 17, 1287\u20131293. https:\/\/doi.org\/10.2147\/OPTH.S409822 (2023).","journal-title":"Clin. Ophthalmol."},{"issue":"15","key":"18376_CR9","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga, P. E. et al. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 37 (15), 3282\u20133289. https:\/\/doi.org\/10.1038\/s41433-023-02505-z (2023).","journal-title":"Eye (Lond)"},{"key":"18376_CR10","doi-asserted-by":"publisher","unstructured":"Kishi, M. et al. Short-Term outcomes of faricimab treatment in Aflibercept-Refractory eyes with neovascular Age-Related macular degeneration. J. Clin. Med. 12 (15). https:\/\/doi.org\/10.3390\/jcm12155145 (2023).","DOI":"10.3390\/jcm12155145"},{"issue":"6","key":"18376_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi, T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J. Ophthalmol. 67 (6), 652\u2013656. https:\/\/doi.org\/10.1007\/s10384-023-01024-4 (2023).","journal-title":"Jpn J. Ophthalmol."},{"issue":"5","key":"18376_CR12","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","volume":"12","author":"S Inoda","year":"2023","unstructured":"Inoda, S. et al. Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular Age-Related macular degeneration in patients with prior treatment history. Ophthalmol. Ther. 12 (5), 2703\u20132712. https:\/\/doi.org\/10.1007\/s40123-023-00779-w (2023).","journal-title":"Ophthalmol. Ther."},{"issue":"17","key":"18376_CR13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani, A. M. et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013\u20096 month results. Eye (Lond). 37 (17), 3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5 (2023).","journal-title":"Eye (Lond)"},{"key":"18376_CR14","doi-asserted-by":"publisher","unstructured":"Tan, C. S. et al. N, Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in singapore: the DIALS study. BMC Ophthalmol. 2020 Aug 6. 20(1): p. 324 https:\/\/doi.org\/10.1186\/s12886-020-01582-y","DOI":"10.1186\/s12886-020-01582-y"},{"issue":"12","key":"18376_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (12), 2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006 (2012).","journal-title":"Ophthalmology"},{"issue":"7","key":"18376_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119 (7), 1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053 (2012).","journal-title":"Ophthalmology"},{"issue":"5","key":"18376_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.5.28","volume":"64","author":"D Sharma","year":"2023","unstructured":"Sharma, D., Zachary, I. & Jia, H. Mechanisms of acquired resistance to Anti-VEGF therapy for neovascular eye diseases. Invest. Ophthalmol. Vis. Sci. 64 (5), 28. https:\/\/doi.org\/10.1167\/iovs.64.5.28 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"18376_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S97653","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel Ther. 10, 1857\u20131867. https:\/\/doi.org\/10.2147\/DDDT.S97653 (2016).","journal-title":"Drug Des. Devel Ther."},{"key":"18376_CR19","doi-asserted-by":"publisher","unstructured":"Ng, B. et al. Real-World data on faricimab switching in Treatment-Refractory neovascular Age-Related macular degeneration. Life (Basel). 14 (2). https:\/\/doi.org\/10.3390\/life14020193 (2024).","DOI":"10.3390\/life14020193"},{"issue":"4","key":"18376_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit, S. A. et al. Clinical outcomes of faricimab in patients with previously treated neovascular Age-Related macular degeneration. Ophthalmol. Retina. 8 (4), 360\u2013366. https:\/\/doi.org\/10.1016\/j.oret.2023.10.018 (2024).","journal-title":"Ophthalmol. Retina"},{"issue":"1","key":"18376_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000514991","volume":"245","author":"J Ahn","year":"2022","unstructured":"Ahn, J. et al. Retinal pigment epithelium tears after Anti-Vascular endothelial growth factor therapy for neovascular Age-Related macular degeneration. Ophthalmologica 245 (1), 1\u20139. https:\/\/doi.org\/10.1159\/000514991 (2022).","journal-title":"Ophthalmologica"},{"issue":"12","key":"18376_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1097\/iae.0000000000003207","volume":"41","author":"A Eshtiaghi","year":"2021","unstructured":"Eshtiaghi, A. et al. Geographic atrophy incidence and progression after intravitreal injections of anti-vascular endothelial growth factor agents for age-related macular degeneration: A Meta-Analysis. Retina 41 (12), 2424\u20132435. https:\/\/doi.org\/10.1097\/iae.0000000000003207 (2021).","journal-title":"Retina"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18376-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:50:02Z","timestamp":1759171802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18376-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wei Kiong Ngo has received consultancy fees from AbbVie, Bayer, Novartis, Roche and Zeiss. He has received lecture fees from AbbVie, Bayer, Novartis, Roche and Zeiss. He has received travel support from AbbVie, Roche and Zeiss.\u00a0Louis Wei Yi Lim has received research grant from Novartis.All the remaining authors declare no conflict of interest.\u00a0Open access fees for this publication were supported by an independent educational grant from Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33672"}}